Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: Results from an ex vivo study

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Shekar, Kiran ^a   Roberts, Jason A ^a   Mcdonald, Charles I ^a   Ghassabian, Sussan ^a   Anstey, Chris ^b   Wallis, Steven C ^a   Mullany, Daniel V ^a   Fung, Yoke L ^c   Fraser, John F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NAMBOUR GENERAL HOSPITAL   (Australia)

^c UNIVERSITY OF THE SUNSHINE COAST   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CASPOFUNGIN; CEFTRIAXONE; CIPROFLOXACIN; FENTANYL; FLUCONAZOLE; LINEZOLID; MEROPENEM; MIDAZOLAM; MORPHINE; THIOPENTAL; VANCOMYCIN; ECHINOCANDIN; LIPOPEPTIDE;

ARTICLE; BLOOD; CENTRIFUGAL PUMP; CONTROLLED STUDY; CRYSTALLOID; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG STABILITY; EX VIVO STUDY; EXPERIMENTAL STUDY; EXTRACORPOREAL OXYGENATION; HUMAN; LIPOPHILICITY; MEMBRANE OXYGENATOR; PARTITION COEFFICIENT; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TEMPERATURE; ADVERSE EFFECTS; CHEMISTRY; MORTALITY; PLASMA; THEORETICAL MODEL;

CEFTRIAXONE; ECHINOCANDINS; EXTRACORPOREAL MEMBRANE OXYGENATION; FLUCONAZOLE; HUMANS; LIPOPEPTIDES; MODELS, THEORETICAL; PLASMA; THIOPENTAL;

EID: 84928262081     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0891-z     Document Type: Article

References (23)

1. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010;76:534-40.
2. Shekar K, Mullany DV, Thomson B, Ziegenfuss M, Platts DG, Fraser JF. Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. Crit Care. 2014;18:219.
3. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63:2769-78.
4. Schmidt M, Tachon G, Devilliers C, Muller G, Hekimian G, Bréchot N, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med. 2013;39:838-46.
5. Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194.
6. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741.e9-18.
7. Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol. 2013;13:7.
8. Testa B, Crivori P, Reist M, Carrupt PA. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des. 2000;19:179-211.
9. Rosenbaum S. Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations. Hoboken, NJ: John Wiley & Sons; 2011. ISBN 9780470569061.
10. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42:403-17.
11. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109-16.
12. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20:309-15.
13. Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, et al. Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc. 2012;14:105-11.
14. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001. US Department of Health and Human Services, Rockville, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf . Accessed 6 Apr 2015.
15. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901-6.
16. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840-51. quiz 859.
17. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99-110.
18. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073-5.
19. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599-610.
20. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33:1018-24.
21. Preston TJ, Hodge AB, Riley JB, Leib-Sargel C, Nicol KK. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234-7.
22. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15:263-6.
23. Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol. 2012;12:29.